Navigation Links
Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine Healive(R)
Date:11/15/2009

BEIJING, Nov. 15 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines, announced today that it was selected by the Shanghai Government to supply its inactivated hepatitis A vaccine, Healive, to the public market of Shanghai. Out of the five vaccine manufacturers that participated in the bidding process, the Shanghai Government awarded Sinovac the entire hepatitis A vaccine purchase order, valued at RMB 20.6 million, or approximately $3 million. Pursuant to the agreement, Sinovac will supply Healive over the next twelve months.

The purchase plan from the Shanghai Government reflects the continued expansion of government purchase programs for vaccines. This is part of the national expanded immunization program (EPI) funded by the Chinese government.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, remarked, "We are pleased that the Shanghai Government selected Sinovac as the sole manufacturer for this $3 million hepatitis A tender offer. Earlier this year, we established growth for Healive in both the public and private pay markets as a strategic goal. At that time, our newly completed filling and packaging plant had made us well positioned to fulfill existing orders, increase our production scale for meeting the demand from both public market and private market and develop new vaccines. We have done just that, securing large Healive purchase orders from the Shanghai government and China's Ministry of Public Health, even as we quickly adapted to develop and commercialize PANFLU.1, a time sensitive H1N1 vaccine. The selection confirms our ability to supply our high quality vaccines pursuant to the Government purchasing programs."

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccine products include Healive® (hepatitis A), Bilive® (combined hepatitis A and B), Anflu® (seasonal influenza), Panflu(TM) (pandemic influenza (H5N1)), and PANFLU.1(TM) (pandemic influenza A (H1N1)). Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, pneumococcal infection, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    Helen G. Yang
    Sinovac Biotech Ltd.
    Tel:  +86-10-8289-0088 x9871
    Fax:  +86-10-6296-6910
    Email:  info@sinovac.com

    Investors:
    Amy Glynn/Stephanie Carrington
    The Ruth Group
    Tel:  +1-646-536-7023/7017
    Email:  aglynn@theruthgroup.com
    scarrington@theruthgroup.com

    Media
    Janine McCargo
    The Ruth Group
    Tel:  656-536-7033
    Email:  jmccargo@theruthgroup.com

SOURCE Sinovac Biotech Co., Ltd.


'/>"/>
SOURCE Sinovac Biotech Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine
2. Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
3. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
4. KV Pharmaceutical Receives Report From Inspector of Elections Certifying Votes To Approve Bylaw Amendments
5. Kensey Nash Receives FDA 510(k) Clearance for Porcine Dermis Biologic Product
6. Sutter Medical Center Receives Certification to Use Ventricular Assist Devices as Destination Therapy
7. Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing
8. ARKRAY, Inc. Receives FDA Clearance for New GLUCOCARD(R) Vital(TM) Blood Glucose Monitoring System
9. Custom Spine Receives 510k Clearance of Regent ACP
10. Sunesis Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia
11. Solos Endoscopy, Inc. Receives Purchase Orders from Catholic Health Initiatives for its MammoView(TM) Product Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Dec. 5, 2016  CVS Health, the nation,s largest ... a perfect score of 100 percent on the Corporate ... CEI is an annual national benchmarking survey and report ... administered by the Human Rights Campaign Foundation. ... that our colleagues, customers and suppliers bring to CVS ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
(Date:12/5/2016)... founder of Spectrum Science Communications , announced today that ... two consecutive years of high double digit growth in fee revenues. ... assumed management of the firm that Seng founded in 1996. Earlier ... of the Year and was selected among the Best Places to ... ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... The V Foundation for Cancer ... a Moment to Lose fundraising campaign. As the V Foundation’s boldest initiative to ... over cancer. The campaign aims to raise $200 million by 2020 and strategically ...
(Date:12/6/2016)... ... December 06, 2016 , ... Just in time for the holiday ... chocolate chip cookie recipe for Honeyville’s new Organic Quinoa Flour product for sale at ... in the near future. , “I think it’s wonderful that a growing number ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... November 25th, when SevenPoint2 released the much-anticipated HydroFX for Water®. This first-of-its-kind ... design. Featuring one of the world’s most powerful antioxidants, molecular hydrogen, HydroFX ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... recount of a powerful woman's story of sacrifice and enlightenment. , ... published author, Carolyn Fryer. Always looking for creative outlets, Carolyn gravitated toward writing ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... only authorized OSHA Training Institute Education Center headquartered in Northern California, has announced ... on providing occupational safety and health training to public sector employees. , “The ...
Breaking Medicine News(10 mins):